Pattern Analysis of Epstein-Barr Virus Viremia and Its Significance in the Evaluation of Organ Transplant Patients Suspected of Having Posttransplant Lymphoproliferative Disorders

American Journal of Clinical Pathology

Volumn 141, Issue 2, 2014, Pages 268-274

  Cho, Young Uk ^a   Chi, Hyun Sook ^a   Jang, Seongsoo ^a   Park, Sang Hyuk ^a   Park, Chan Jeoung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Epstein Barr virus; Pattern analysis; Posttransplant lymphoproliferative disorder; Quantitative real time PCR; Viremia

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; VIRUS LOAD; AREA UNDER THE CURVE; ORGAN TRANSPLANTATION; PATTERN ANALYSIS; QUANTITATIVE REAL-TIME PCR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA; VIROLOGY;

EPSTEIN-BARR VIRUS; PATTERN ANALYSIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; QUANTITATIVE REAL-TIME PCR; VIREMIA;

AREA UNDER CURVE; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; VIREMIA;

EID: 84895159389     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP9WYEXKOL9YUV     Document Type: Article

References (18)

1. Swerdlow SH, Webber SA, Chadburn A, et al. Posttransplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:343-349.
2. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010;23:350-366.
3. Ishihara M, Tanaka E, Sato T, et al. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients. Clin Nephrol. 2011;76:40-48.
4. Nakanishi C, Kawagishi N, Sekiguchi S, et al. Posttransplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience. Surg Today. 2012;42:741-751.
5. Yoon SO, Yu E, Cho YM, et al. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990-2009. Clin Transplant. 2012;26:67-73.
6. Chen DB, Song QJ, Chen YX, et al. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2013;97:117-124.
7. Holman CJ, Karger AB, Mullan BD, et al. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant. 2012;26:741-747.
8. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165-1171.
9. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98:972-978.
10. Aalto SM, Juvonen E, Tarkkanen J, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis. 2007;45:1305-1309.
11. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13:41-54.
12. Parker A, Bowles K, Bradley JA, et al. Diagnosis of posttransplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS guidelines. Br J Haematol. 2010;149:675-692.
13. Schober T, Framke T, Kreipe H, et al. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation. 2013;95:240-246.
14. Ghorbrial IM, Habermann TM, Macon WR, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005;79:244-247.
15. Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol. 2011;86:206-209.
16. Choi JH, Park BB, Suh C, et al. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders. J Korean Med Sci. 2010;25:523-526.
17. Dierickx D, Tousseyn T, Sagaert X, et al. Singlecenter analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma. 2013;54:2433-2440.
18. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multiinstitutional study. Lancet. 2006;367:233-239.